All Teplizumab articles
-
NewsSanofi wins EU approval for its type 1 diabetes biologic Teizeild
The European Commission’s decision will make the product the first disease-modifying treatment to be available for the condition in Europe.
-
NewsSanofi’s Tzield type 1 diabetes immunotherapy wins UK first
Becomes the first monoclonal antibody for the condition to be approved by the MHRA and advances the pharma company’s ambitions in diabetes.
-
NewsPotential blockbuster drugs to watch in 2023
Lecanemab for Alzheimer's and the first potential gene therapy primed for US launch for haemophilia A are two potential blockbuster Drugs to Watch™, says a 2023 report.